O R I G I N a L I N V E S T I G a T I O N Open Access

Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial Abstract Background: Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events.We aimed to establish whether CVD event rates were influenced by the metabolic syndrome as defined by the World Health Organisation (WHO), the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) and the International Diabetes Federation (IDF) and to determine which component(s) of the metabolic syndrome (MS) conferred the highest cardiovascular risk in in 4900 patients with type 2 diabetes allocated to placebo in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial.

[1]  International Association for the Study of Obesity , 2018, The Grants Register 2019.

[2]  N. J. Wareham,et al.  The hypertriglyceridemic-waist phenotype and the risk of coronary artery disease: results from the EPIC-Norfolk Prospective Population Study , 2010, Canadian Medical Association Journal.

[3]  G. de Simone,et al.  The issue of body size between methods and substance. , 2008, Journal of hypertension.

[4]  R. D'Agostino,et al.  Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus , 2005, Circulation.

[5]  Paul Zimmet,et al.  The metabolic syndrome—a new worldwide definition , 2005, The Lancet.

[6]  L. Robinson,et al.  Metabolic syndrome, a cardiovascular disease risk factor: role of adipocytokines and impact of diet and physical activity. , 2004, Canadian journal of applied physiology = Revue canadienne de physiologie appliquee.

[7]  Seppo Lehto,et al.  Gender difference in the impact of type 2 diabetes on coronary heart disease risk. , 2004, Diabetes care.

[8]  L. Bouter,et al.  Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease. 10-year follow-up of the Hoorn Study. , 2003, European heart journal.

[9]  B. Howard,et al.  Relation of insulin resistance to markers of preclinical cardiovascular disease: the Strong Heart Study. , 2003, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[10]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[11]  Ronald Klein,et al.  Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. , 2002, Diabetes care.

[12]  G. Colditz,et al.  The disease burden associated with overweight and obesity. , 1999, JAMA.

[13]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[14]  S. Grundy,et al.  Relationships of generalized and regional adiposity to insulin sensitivity in men. , 1995, The Journal of clinical investigation.

[15]  R. Krauss,et al.  LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  B V Howard,et al.  Obesity in the Pima Indians: its magnitude and relationship with diabetes. , 1991, The American journal of clinical nutrition.

[17]  P. Toth.  Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the field randomised trial , 2012 .

[18]  F. Galvano,et al.  Normal-weight obese syndrome: early inflammation? , 2007, The American journal of clinical nutrition.

[19]  S. Teutsch,et al.  THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (NHANES III); NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP). NCEP-DEFI NED METABOLIC SYNDROME, DIABETES, AND PREVALENCE OF CORONARY HEART DISEASE AMONG NHANES III PARTICIPANTS AGE 50 YEARS AND OLDER , 2003 .

[20]  I. Shapira,et al.  Cardio Vascular Diabetology Open Access Original Investigation the Association of Higher Levels of Within-normal-limits Liver Enzymes and the Prevalence of the Metabolic Syndrome , 2022 .